May 22 |
Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric Disorders
|
Apr 17 |
Protagenic Therapeutics’ Innovative Peptide PT00114 to be Highlighted at Boston Summit
|
Apr 1 |
Earnings Scheduled For April 1, 2024
|
Mar 27 |
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders
|
Mar 25 |
Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call
|
Feb 13 |
Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders
|